When Wegovy (semaglutide 2.4 mg) launched in 2021, it represented the most significant advance in obesity treatment in a generation — delivering average weight losses of around 15% in clinical trials. Since then, GLP-1 receptor agonists have transformed the landscape of metabolic medicine.
On March 19, 2026, that landmark got extended further. The FDA approved Wegovy HD (semaglutide 7.2 mg), delivering what Novo Nordisk describes as the highest weight loss yet achieved by any Wegovy injection dose.
The STEP UP Trial
The approval was based on the STEP UP clinical trial program, which evaluated the 7.2 mg once-weekly injectable in adults with obesity:
- Mean weight loss: 20.7% over 72 weeks — compared to roughly 15% with the 2.4 mg dose
- One in three participants (≈33%) achieved 25% or greater weight loss
- A companion trial in people with obesity and type 2 diabetes (STEP UP T2D) showed a mean weight loss of 14.1%
- Safety and tolerability were consistent with the established semaglutide profile
The 7.2 mg dose is already approved in the EU and UK, where it has been available since late 2025. The US approval brings global alignment on the highest-dose option.
Context and Significance
Obesity affects over 1 billion people worldwide and is a major driver of cardiovascular disease, type 2 diabetes, joint disease, and several cancers. For decades, medical treatment options were limited and largely ineffective at sustained weight loss.
The GLP-1 class has changed that dramatically. Wegovy (at 2.4 mg) already demonstrated that it could reduce the risk of major cardiovascular events in patients with obesity and established heart disease — the first obesity drug ever to show cardiovascular benefit. The higher 7.2 mg dose extends efficacy to a population that needed more.
Novo Nordisk anticipates launching Wegovy HD in the US in April 2026. Patients who have already been on the 2.4 mg dose for at least four weeks may be considered candidates for the higher dose.
With oral GLP-1 options like orforglipron also advancing through FDA review, the field continues to move quickly toward a range of effective options — injectable and oral — for the billions of people living with obesity globally.
Sources: Novo Nordisk press release, March 19, 2026 · FDA approval notification · HCP Live · Healio · ScienceAlert · STEP UP trial data
